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ABSTRACT 
Purpose 
Invasion and migration are key processes in the malignant phenotype of glioblastoma 
and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown 
synergy with chemo- and radiotherapy in vitro and promising activity in recurrent 
glioblastoma. This multicenter, open-label, phase I/IIa study investigated the efficacy 
and safety of cilengitide in combination with standard chemoradiotherapy in newly 
diagnosed glioblastoma. 
Patients and Methods 
Patients (≥18 to ≤70 years) were treated with cilengitide (500 mg) administered twice 
weekly i.v. in addition to standard radiotherapy with comcomitant and adjuvant  
temozolomide. Treatment was continued until disease progression or for a maximum of 
35 weeks. The primary endpoint was progression-free survival (PFS) at 6 months. 
Results 
Fifty-two patients (median age 57 years; 62% male) were included. Six- and 12-month 
PFS rates were 69% (95% confidence interval [CI], 54-80%) and 33% (95% CI, 21-
46%). Median PFS was 8 months (95% CI, 6.0-10.7). Twelve- and 24-month overall 
survival (OS) rates were 68% (95% CI, 53-79%) and 35% (95% CI, 22-48%). Median 
OS was 16.1 months (95% CI, 13.1-23.2). PFS and OS were longer in patients with 
tumors with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation 
(13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 
months). The combination of cilengitide with temozolomide and radiotherapy was well 
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tolerated, with no additional hematologic or nonhematologic toxicity. No pharmacokinetic 
interactions between temozolomide and cilengitide were identified. 
Conclusion 
Compared with historical controls, the addition of concomitant and adjuvant cilengitide to 
standard chemoradiation demonstrated promising activity in patients with glioblastoma 
with MGMT promoter methylation. 
 
 5
INTRODUCTION 
Glioblastoma, the most aggressive and most common primary brain tumor in adults1-3, is 
an intensely vascularized, invasive tumor with a high propensity to induce 
angiogenesis.4 The standard of care for newly diagnosed glioblastoma includes surgical 
resection where feasible, involved-field radiotherapy (RT) and concomitant 
temozolomide (TMZ) chemotherapy followed by up to 6 months of adjuvant TMZ.5 
Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is a 
putative predictive marker for benefit from TMZ plus RT.6-8 Despite these diagnostic and 
therapeutic advances, most patients with glioblastoma still die within 2 years. 
Cilengitide (EMD 121974) is the first agent in a novel class of integrin-directed 
anticancer therapies reaching the clinic.9 Integrins are heterodimeric transmembrane 
receptors that play a key role in cellular interactions, adhesion to the extracellular matrix, 
and cell migration.10 Cilengitide is a cyclized arginine–glycine–aspartic acid (RGD)-
containing pentapeptide that selectively binds the cell surface receptors αVβ3 and αVβ5, 
which are expressed on activated endothelial cells during angiogenesis.11-12 Moreover, 
cilengitide may act directly on V3- and V5-expressing tumor cells, depriving them of 
important signals involved in survival and growth, and indirectly by inhibiting 
angiogenesis and thereby tumor growth.13-14 Glioblastomas express the target integrins 
of cilengitide on activated endothelial cells and on tumor cells.15 
Single-agent cilengitide has been investigated in patients with recurrent glioblastoma in 
phase I and II studies and has shown an excellent safety profile with little toxicity and 
promising antitumor activity.16-18 Preclinical models have indicated a synergistic effect 
when cilengitide is combined with RT19-20 or with an alkylating agent (data on file, Merck 
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KGaA, Darmstadt). There is thus a strong scientific rationale for combining cilengitide 
with chemoradiotherapy to improve tumor control and inhibit tumor cell adhesion and 
migration. 
This study investigated the efficacy and safety of concomitant and adjuvant cilengitide 
added to standard chemoradiation in patients with newly diagnosed glioblastoma. 
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PATIENTS AND METHODS 
Study Design 
This multicenter, open-label, single-arm, phase I/IIa trial investigated the efficacy and 
safety of cilengitide added to RT with concomitant and adjuvant TMZ in patients with 
newly diagnosed glioblastoma. It was conducted in accordance with the Declaration of 
Helsinki, Good Clinical Practice, and International Conference on Harmonisation 
recommendations. The study protocol and informed-consent form were approved by 
Ethics Committees at each investigational site in accordance with local legislation. 
Written informed consent was obtained from each patient prior to study entry. Primary 
endpoint was the PFS rate at 6 months. Secondary endpoints were OS, safety, and 
pharmacokinetics. The influence of MGMT promoter methylation status on efficacy was 
investigated in a prospectively planned subgroup analysis. 
 
Patient Selection 
Main inclusion criteria were age ≥18 to ≤70 years; newly diagnosed, histologically 
proven supratentorial glioblastoma (World Health Organization [WHO] grade IV); 
Eastern Cooperative Oncology Group (ECOG) performance status ≤2; adequate renal 
(creatinine ≤1.5 × upper limit of normal [ULN] or creatine clearance rate ≥60 mL/min), 
hepatic (total bilirubin ≤1.5 × ULN and serum transaminases ≤2.5 × ULN), and 
hematologic (absolute neutrophil count ≥1,500/mm3, platelets ≥100,000/mm3, and 
hemoglobin ≥10 g/dL) function. Tumor tissue was required for central pathology review 
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and MGMT promoter methylation analysis. An interval of ≥3 weeks but ≤5 weeks 
between surgery or biopsy and enrollment was required. 
 
Exclusion criteria were: prior chemotherapy or RT or a history of malignancy in the 
previous 5 years; previous anti-angiogenic therapy; and recent/concurrent treatment 
with other experimental therapies. Patients with planned surgery for other diseases, a 
history of peptic ulcer within the last 6 months, or a history of coagulation disorder 
associated with bleeding or recurrent thrombotic events were also excluded. A negative 
pregnancy test and adequate contraception were mandatory. 
 
Treatment 
RT and TMZ were administered as previously described.5 Fractionated 3-dimensional 
conformal radiotherapy was delivered with a linear accelerator at 2 Gy per fraction for a 
total of 60 Gy in 30 fractions (5 days per week). The target volume was planned from 
postoperative magnetic resonance imaging (MRI) studies and included all gross disease 
plus a margin of 2-3 cm. TMZ 75 mg/m2/day was administered orally 7 days each week 
from the first to the last day of RT. After a 4-week break, adjuvant TMZ 150–200 
mg/m2/day was given for 5 consecutive days every 4 weeks for a total of 6 cycles.  
Cilengitide was administered at a flat dose of 500 mg as a 1-hour intravenous infusion 
twice weekly on days 1 and 4 (or occasionally on days 2 and 5), starting 1 week before 
(week -1) chemoradiation. Cilengitide was continued until progression or until the end of 
adjuvant TMZ, i.e., for up to 35 weeks, or until the occurrence of unacceptable adverse 
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events (AEs). It was administered approximately 2 h before TMZ, RT was delivered 
approximately 60 min after TMZ.  
 
Pharmacokinetics (PK) 
Pharmacokinetic analyses were performed in a subset of 13 patients (4 patients 
receiving enzyme-inducing antiepileptic drugs (EIAED), 4 on non-EIAED, and 5 patients 
with no anticonvulsants) to identify potential interactions between cilengitide and TMZ 
when administered concomitantly. Blood samples (4 mL) were taken for determination of 
cilengitide plasma concentrations before dosing and 1, 1.5, 2, 3, 4, 8, and 24 h after 
starting the infusion on day 1 of weeks 1, 2, 8, and 12; TMZ plasma concentrations were 
determined before dosing and 0.25, 0.5, 1, 2, 3, 4, 6, and 8 h after administration on 
days 3 and 4 of week 2. Cilengitide and TMZ plasma concentrations were determined 
using validated high-performance liquid chromatography and liquid chromatography 
tandem mass spectrometry 21-22. The PK parameters of cilengitide and TMZ were 
calculated from plasma concentration data according to non-compartmental standard 
methods using the PK software program KINETICATM. 
 
MGMT status 
MGMT gene promoter methylation status was determined by methylation-specific 
polymerase chain reaction (PCR), as previously described.7,23 Genomic DNA was 
isolated from macrodissected paraffin sections or cryosections of glioblastoma tissue 
(Ex-Wax DNA Extraction Kit S4530, Chemicon, or Qiagen genomic kit, respectively) and 
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subjected to bisulfite modification using the EpiTect kit (Qiagen). Unmethylated cytosine, 
but not its methylated counterpart, is modified into uracil by bisulfite treatment. 
Methylation-specific PCR was performed in a nested two-step approach. The results 
were confirmed in an independent experiment, starting with reisolation of DNA from the 
tumor. PCR products were separated on 4% agarose gels. 
 
Efficacy and Safety Assessments 
A gadolinium-enhanced MRI scan was performed within 1 week before the first dose of 
cilengitide for patients who had undergone a tumor biopsy or <48 h after surgery for 
patients who had undergone open tumor resection. MRI was repeated 3-4 weeks after 
the end of RT and every 8 weeks thereafter for 6 months, subsequently every 3 months. 
Progression was based on investigators’ clinical and radiological assessment according 
to Macdonald criteria.24 
Safety was evaluated by descriptively summarizing AEs, laboratory assessments, and 
physical examinations, including ECOG performance status, vital signs, neurological 
examinations, hematology and coagulation parameters, weekly blood counts, serum 
chemistry, urinalysis, chest x-ray, and electrocardiogram. All treatment-emergent AEs 
were recorded. AEs possibly related to treatment with chemoradiotherapy or cilengitide 
and events that could not be attributed to another cause were reported as treatment-
related AEs. 
 
Statistical Methods 
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All analyses were performed on the intent-to-treat population defined as all patients who 
received at least one dose of cilengitide. Patient demographics and AEs are descriptive. 
The primary endpoint was the PFS rate at 6 months. PFS was defined as the time from 
start of cilengitide treatment until progression or death from any cause. In a sample of 
50 patients, the target was to obtain a 6-month PFS rate of ≥65%. OS was defined as 
the time from the start of cilengitide treatment until death from any cause. Kaplan-Meier 
survival curves (product-limit estimates) were produced with a summary of associated 
statistics (median survival time, 6-monthly survival rate estimates) including the 
corresponding two-sided 95% confidence intervals (CIs).   
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RESULTS 
 
Patient Characteristics 
Of 59 patients screened, 52 met the inclusion criteria and were treated at 15 sites in 
Switzerland, Germany, and Belgium. Reasons for non-inclusion of screened patients 
were: failure to meet inclusion/exclusion criteria (n = 5), AEs (n = 1), or withdrawal of 
consent (n = 1). Patient characteristics are summarized in Table 1. Median age was 57 
years, and most patients had a performance status of 0 or 1. Twenty-three patients had 
a gross total resection, 20 patients had a partial resection, 9 had only a diagnostic 
stereotactic biopsy. Thirty-five patients received AED at baseline, including 19 patients 
receiving EIAED. Histology was centrally confirmed as glioblastoma in 92% of patients. 
Central review reclassified two patients as anaplastic astrocytoma (WHO grade III). A 
confirmation of the diagnosis was not possible in two patients due to insufficient or 
missing samples. MGMT promoter methylation status could be determined in 45 
patients (87%) and approximately half (23) had MGMT promoter methylation, a 
distribution comparable to our previous trials.6-8  . The frequency observed in this study is 
similar to the randomized phase III EORTC-NCIC study (46%).7  
 
Treatment Delivery 
Fifty patients (96%) completed combination treatment with cilengitide plus TMZ and RT; 
23 patients (44%) completed the planned study period of 35 weeks, including all 6 
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cycles of maintenance TMZ. Reasons for early discontinuation were disease 
progression (n = 19, 37%), AEs (n = 9, 17%), or withdrawal of consent (n = 1, 2%).  
 
Efficacy 
At the time of this analysis after a median follow-up of 34 months (minimum follow-up 24 
months), 43 patients (83%) have progressed and 34 patients (65%) have died (Table 2). 
The 6-month PFS rate (primary endpoint) was 69% (95% CI, 54-80%). The median PFS 
was 8.0 months (95% CI, 6.0-10.7). The median OS was 16.1 months (95% CI, 13.1-
23.2); 1- and 2-year OS rates were 68% (95% CI, 53-79%) and 35% (95% CI, 22-48%). 
Subgroup analyses for known clinical prognostic factors demonstrated prolonged PFS 
and OS in patients younger than 50 years and in patients who had debulking surgery. 
PFS was significantly longer in patients with tumors with MGMT promoter methylation 
than those without (Fig. 1; Table 2). Six-months, 12-months, and median PFS were 91% 
(95% CI, 70-98%), 52% (95% CI, 30-70%), and 13.4 months (95% CI, 8.6-22.8) in 
patients with MGMT promoter methylation v 41% (95% CI, 21-60%), 9% (95% CI, 2-
25%), and 3.4 months (95% CI, 2.3-7.1) in patients without. OS was also prolonged in 
patients with MGMT promoter methylation (Fig. 2, Table 2). Twelve-, 18-, and 24-month 
OS were 91% (95% CI, 69-98%), 68% (95% CI, 45-84%) and 46% (95% CI, 25-64%) in 
patients with MGMT promoter methylation versus 51% (95% CI, 28-70%), 25% (95% CI, 
9-45%), and 20% (95% CI, 6-40%) in patients without. 
 
Pharmacokinetics (PK) 
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Mean plasma time concentration curves and PK parameters for cilengitide and TMZ are 
summarized in Supplementary Tables 1 and 2 and in Fig. 3. Mean cilengitide plasma 
concentration time profiles and mean PK parameters (Cmax, tmax, AUC, t1/2, CL and 
Vz) were similar across the weeks of cilengitide treatment, indicating that the PK of 
cilengitide is independent from treatment time and neither influenced by co-treatment 
with TMZ alone nor with TMZ chemoradiation. Maximum plasma concentrations of 
cilengitide were reached at 1 h post-dose, i.e., at the end of infusion. Mean systemic CL 
of cilengitide ranged from 6.72 to 7.51 L/h, the mean terminal half-life (t1/2) from 2.02 to 
2.16 h, and the mean volume of distribution (Vz) from 19.6 to 21.9 L, nominally 
equivalent to the extracellular fluid volume. There was no apparent accumulation of 
cilengitide upon repeated administration. 
Also for TMZ plasma concentration time profiles and mean PK parameters were similar 
across treatment periods observed indicating that the PK of TMZ is not influenced by 
concomitant treatment with cilengitide. No influence of the concomitant administration of 
EIAED was evident. Maximum plasma concentrations of TMZ were reached within 1 h 
after oral administration. The mean systemic CL of TMZ was 7.42 L/h/m² on day 3 and 
7.56 L/h/m² on day 4, the mean t1/2 was 1.84 h on both days and the Vz was 19.7 L/m² 
on day 3 and 20.1 L/m² on day 4. Overall, the PK parameters of TMZ were in good 
agreement with published data25 and did not appear to be influenced by concomitant 
treatment with cilengitide and RT. 
 
Safety 
Kommentar [RS1]: To be 
confirmed by Merck. 
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The combination of cilengitide with standard chemoradiation was safe and well 
tolerated. Treatment-related AEs were usually mild to moderate and in the range 
previously observed with radiotherapy plus TMZ alone (Tables 3 and 4). Constitutive 
symptoms (nausea, headache, fatigue, vomiting, and anorexia) were the most common 
nonhematologic AEs. Seven patients (14%) had treatment-related AEs leading to 
withdrawal of further treatment including thrombocytopenia, asthenia, hepatitis, raised 
liver enzymes, aphasia related to cerebral hemorrhage, cerebral hemorrhage, memory 
impairment, lower limb paresthesias, pulmonary embolism, and deep vein thrombosis. 
Treatment-emergent AEs unlikely to be related to treatment included thrombosis and 
pulmonary emboli in two patients, further complicated in one patient by a fatal 
intracranial bleed 18 days after the last cilengitide administration. A minor intracranial 
hemorrhage was detected on MRI in a patient after a seizure. One patient with a history 
of diverticulosis required surgery for intestinal perforation; cilengitide therapy was 
subsequently resumed without further complications. Grade 1/2 hypertension was 
observed in 5 patients(9.6%) and mild proteinuria in 1 patient. Other toxicities were one 
case each of reversible peripheral grade 2 neuropathy not otherwise explained and 
idiosyncratic liver toxicity likely related to valproic acid. One patient died due to tumor 
progression within 28 days of the last dose of cilengitide. No safety differences were 
observed between patients with versus without MGMT promoter methylation (data not 
shown). 
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DISCUSSION 
Various strategies are pursued to improve the outcome for newly diagnosed 
glioblastoma patients by adding new agents to the standard of radiotherapy plus 
concomitant and adjuvant TMZ. Here we report for the first time the use of an integrin 
inhibitor in newly diagnosed glioblastoma. The addition of cilengitide to the combined 
chemoradiation regimen showed clinical activity and was well tolerated. A total of 14% of 
patients discontinued treatment due to possibly treatment related adverse events, 
slightly higher than in the EORTC-NCIC experience 5; this may in part be explained by 
the increased monitoring due to the twice weekly administration schedule. Overall, the 
toxicity was comparable to other reports with cilengitide, and no single AE could be 
specifically attributed to the study drug..16-18, 29 + ref. NABTT 9911. Similarly, no increase 
in thromboembolic events and hemorrhagic complications was evident with the addition 
of this anti-angiogenic agent.   
 
Of note, no severe hemorrhagic complications or wound-healing problems were 
observed in this population of patients treated shortly after brain surgery. Our safety 
findings are similar to those of another phase II study in which two doses of cilengitide 
(500 mg or 2000 mg) were administered before second surgery at recurrence.16 Even 
though the last cilengitide dose was given 24 h before surgery, no relevant hemorrhagic 
or wound-healing AEs were observed. The pharmacokinetics of cilengitide and of TMZ 
in combination with RT were comparable to published data as single agents,21-22,25 and 
no pharmacokinetic interaction or accumulation after repeated dosing was observed 
(Supplementary Tables 1 and 2, Figure 3). 
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The primary endpoint was the 6-months PFS rate, which was 69% (95% CI, 54-80%) – 
an improvement of about 15% over RT plus TMZ alone5 – and thus met the predefined 
target of success of >65%. After a minimum follow-up of 2 years, six patients have not 
progressed. OS also compares favorably with previous reports, with a median of 16.1 
months (95% CI, 13.1-23.2) and a 2-year survival rate of 35% (95% CI, 22-48%). A 
better outcome was seen in patients who had undergone debulking surgery. In the 
context of drugs like cilengitide, it is reasonable to assume that the inhibition of 
attachment and migration may become clinically relevant mainly after elimination of the 
tumor bulk. 
The benefit of adding cilengitide, at least at the dose and schedule chosen here, to the 
standard regimen of TMZ and RT followed by TMZ alone appears to be limited to 
patients with glioblastoma with MGMT promoter methylation. The reasons for this non-
intuitive interrelation remain unclear at present. No synergistic effects were identified for 
the combination of cilengitide and TMZ in vitro, and the MGMT status per se has no 
effect on the biological activity of cilengitide.13 We speculate that cilengitide-induced 
vascular normalization improves the delivery of TMZ to tumor tissue, with a preferential 
benefit for patients with MGMT promoter methylation. This is in accordance with the 
observation of a better prognosis associated with increased expression of a signature 
for tumor endothelium markers in the treatment arm of the EORTC-NCIC study which 
may be linked to a better perfusion of the tumor with TMZ.26 
Could the favorable results be related to an increased incidence of pseudoprogression 
in patients with MGMT-methylated tumors27 which was successfully treated by 
cilengitide? We believe that this is not the case. In fact, it remains to be confirmed that 
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patients with MGMT promoter methylation are more likely to experience 
pseudoprogression, and unlike the VEGF antibody bevacizumab,28 there is no data to 
suggest that cilengitide will ameliorate treatment-induced imaging changes in 
glioblastoma. 
On the other hand, orthotopic in vivo glioblastoma models demonstrated both sensitivity 
to cilengitide20and striking synergy between cilengitide and RT.19 One may speculate 
that patients without MGMT promoter methylation may require higher doses than 500 
mg to experience such a radiosensitizing effect. We used a 500 mg dose based on a 
prior phase I dose-escalation study, in which dose-limiting toxicity was not reached at 
doses up to 2400 mg/m2 and responses were observed at both lower and higher 
doses.18 However, there is now increasing evidence that cilengitide was underdosed in 
our trial: A randomized trial evaluated tissue penetration of of cilengitide in patients 
treated prior to surgery for recurrent disease demonstrating higher drug concentrations 
in the tumor tissue at 2000 mg of cilengitide compared to 500 mg only.17  Two 
randomized phase II studies evaluated a lower (500 mg) and higher (2000 mg) 
cilengitide dose in recurrent and newly diagnosed glioblastoma, both trials showed 
consistently a better outcome for patients treated with at the 2000 mg dose level. 16, 29 In 
newly diagnosed GBM patients cilengitide in addition to TMZ/RT demonstrated a 
median survival of 17 months and 21 months for the 500 mg and 2000 mg doses, 
respectively.29  
Despite encouraging clinical activity throughout all phase I and II trials, a number of 
preclinical observations have recently provoked controversy about potential counter-
productive effects of integrin antagonism in cancer treatment, including the paradoxical 
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promotion of angiogenesis and metastasis at extremely low doses.30 A detailed review 
of these studies is beyond the scope of this discussion. Nevertheless, at the dose used 
in our regimen, sufficiently high tissue concentrations of cilengitide are achieved.31 
Based on the results of the present trial and supportive data from complementary trials 
preclinical and clinical studies, a randomized phase III trial (CENTRIC, EORTC 26071-
22072, NCT00689221) was launched at the end of 2008. The standard arm corresponds 
to standard TMZ/RT chemoradiation 5 whereas the experimental arm investigates the 
addition of high-dose (2000 mg cilengitide to TMZ/RT. Eligibility is restricted to patients 
with a methylated MGMT promoter, speculating that this anti-angiogenic strategy is most 
effective in the presence of an active chemotherapy regimen. The excellent safety 
profile and the observation of some early relapses after cessation of cilengitide suggest 
that the discontinuation of cilengitide after completion of 6 months in the trial reported 
here may have been premature. Indeed, mechanistic considerations warrant prolonged 
integrin inhibition. Accordingly, cilengitide will be administered until progression or for up 
to 18 months in the CENTRIC trial. 
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Table 1. Baseline Patient Characteristics (n = 52) 
Characteristic Number of patients (%) 
Median age, years (range) 57 (32-68) 
Sex 
 Male 
 Female 
 
32 (62) 
20 (38) 
ECOG performance status 
 0 or 1 
 2 
 
48 (92) 
4 (8) 
 26
Prior treatment 
 Corticosteroids 
 Debulking surgery 
  Complete resection 
  Partial resection  
  Biopsy 
 
43 (83) 
43 (83) 
23 (44) 
20 (39) 
9 (17) 
Independent histopathologic confirmation of glioblastoma 
Other 
 Anaplastic astrocytoma (WHO grade III) 
 Material insufficient or missing for diagnosis 
48 (92) 
 
2 (4) 
2 (4) 
MGMT promoter status 
 Methylated 
 Unmethylated 
 Unknown 
 
23 (44) 
22 (42) 
7 (13) 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; WHO, World Health 
Organization. 
 27
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Table 2. Survival in the ITT Population and by MGMT Status 
Endpoint ITT Population 
(n = 52) 
Patients With 
MGMT Promoter 
Methylation 
(n = 23) 
Patients Without 
MGMT Promoter 
Methylation 
(n = 22) 
 29
Progression-free survival 
 12 months 33 (21-46) 52 (30-70) 9 (2-25) 
 18 months  19 (9-31) 33 (15-52) 5 (0-19) 
 24 months 15 (6-26) 28 (12-48) 5 (0-19) 
Overall survival 
 30
Median OS, months 
(95% CI) 
16.1 (13.1-23.2) 23.2 (15.5-NR) 13.1 (9.7-17.6) 
 31
 6 months  90 (78-96) 100 (NA) 81 (57-93) 
 
Table 3. Hematologic Toxicity Reported by Laboratory Values, Irrespective of 
Relationship to Study Drug (n = 52) 
 32
 Number of patients (%) 
Lymphocytopenia 22 (42) 29 (56) 51 (98) 
 33
Thrombocytopenia 29 (56) 7 (14) 36 (69) 
Neutropenia 9 (17) 5 (10) 14 (27) 
 
 34
 
Table 4. Treatment-Related Nonhematologic Adverse Events* (n = 52) 
 35
 Number of patients (%) 
 36
Anorexia 15 (29) 1 (2) 16 (31) 
 
 37
Supplementary Table 1. Mean plasma PK parameters of cilengitide by week 
 38
Week Statistic PK Parameter 
 39
  
Cmax 
 [µg/mL] tmax 
 [h] 
AUC0- 
[µg/mL*h] 
z 
[1/h] 
t1/2 
[h] 
MRT 
[h] 
CL 
[L/h]
 40
1 N 11 11 6 6 6 6 6 6 6 
 41
  Mean 25.6 1.14 72.1 0.350 2.02 2.75 7.51 21.9 21.0 
 42
  %CV 27.1 9.2 27.1 16.6 15.5 17.5 35.1 40.1 48.6 
 43
  Min 13.6 0.92 45.5 0.241 1.55 2.38 5.45 12.2 13.0 
 44
8 N 9 9 8 8 8 8 8 8 8 
 45
  %CV 21.8 6.8 38.8 28.8 34.7 28.7 28.2 10.3 13.5 
 46
  Min 17.0 1.08 46.4 0.299 1.48 2.55 5.14 16.8 15.4 
N: total number of subjects; Min: minimum; Max: maximum; %CV: percentage of coefficient variation. 
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Supplementary Table 2. Mean plasma PK parameters of temozolomide by day in week 
2 
 48
Day Statistic PK Parameter 
 49
  Cmax 
[ng/mL] 
tmax 
[h] 
AUC0- 
[ng/mL*h] 
z 
[1/h] 
t1/2 
[h] 
MRT 
[h] 
CL/f 
[L/h/m²] 
Vz/f 
[L/m²] 
Vss/f 
[L/m²] 
 50
  Mean 3497 0.95 10269 0.380 1.84 3.10 7.42 19.7 23.0 
 51
4 N 10 10 8 8 8 8 8 8 8 
 52
  Max 4982 2.00 12617 0.474 2.47 3.79 9.70 27.0 30.0 
 
 53
Figure legends 
 
Fig 1a. Kaplan-Meier estimate for progression-free survival (all patients) 
 
Fig 1b. Kaplan-Meier estimates for progression -free survival by MGMT promoter 
methylation status 
 
Fig 2a. Kaplan-Meier estimate for overall survival (all patients) 
 
Fig 2b. Kaplan-Meier estimate for overall survival by MGMT promoter methylation 
status. 
 
Fig 3a. Comparison of the mean (± s.d.) plasma cilengitide concentrations between 
weeks 
 
Fig 3b. Comparison of the mean (± s.d.) plasma TMZ concentrations between days in 
week 2 
 
 54
Fig 1a. 
 
 
 
Fig 1b. 
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Fig 2a. 
 
 
 
Fig 2b. Kaplan-Meier estimate for duration of overall survival according to methylation 
status. 
 56
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Fig 3a. Comparison of the mean (± s.d.) plasma cilengitide concentrations between 
Weeks 
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Fig 3b. Comparison of the mean (± s.d.) plasma TMZ concentrations between days in 
Week 2 
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